2 results
Approved WMORecruiting
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Approved WMOPending
Primary objectiveTo compare the effect on psoriasis symptoms of an adjustable brodalumab dosage regimen to standard brodalumab treatment in subjects with moderate-to-severe psoriasis and a body weight >=120 kg.Secondary objectives:To evaluateā¦